Biogen announced plans to present data on the company’s portfolio, including the controversial medicine Aduhelm (aducanumab), at the annual Clinical Trials on Alzheimer’s Disease conference (CTAD) scheduled for November 9-12.

An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.

75 top Alzheimer’s and dementia experts collaborated on a 10-year strategic plan for researchers, policymakers and caregivers   May 21, 2020 –– A new report released today by AARP and the Women’s Alzheimer’s Movement (WAM) synthesizes years of data and findings to help explain why women are disproportionately affected by Alzheimer’s disease. Two-thirds of the 5.8 […]

Axsome Therapeutics announced that the company’s AXS-05 met the primary endpoint in the ADVANCE-1 Phase II/III clinical trial for agitation in patients with Alzheimer’s disease.

Eagle Pharmaceuticals Inc. and the University of Pennsylvania agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease.

Purchasers of Allergan Plc’s Namenda asked a federal judge to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer’s medication off the market.

In honor of November being Alzheimer’s Awareness month, BioSpace evaluated the current therapies, drugs in the pipeline and disease outlook.

Drugmaker Eli Lilly and Company said early results from a study suggest that Apple Inc. devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer’s disease dementia and those without symptoms.

Eisai Co. Ltd. initiated Phase 3 clinical trials of the Alzheimer’s treatment BAN2401 one day after the Japanese drugmaker and U.S. partner Biogen Inc. scrapped studies for the Alzheimer’s drug aducanumab.

Researchers with the University of California, Los Angeles (UCLA) Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice.